Advanced search
Publication Cover
Cancer Investigation Volume 16, 1998 - Issue 6
Submit an article Journal homepage
9
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Carboplatin and Paclitaxel for Previously Treated Patients with Non-small-cell Lung Cancer

Veronica Roa Division of Hematology/Oncology, Medical College of Virginia Virginia Commonwealth University Richmond, Virginia
,
Anita Conner Division of Hematology/Oncology, Medical College of Virginia Virginia Commonwealth University Richmond, Virginia
&
R. Brian Mitchell Division of Hematology/Oncology, Medical College of Virginia Virginia Commonwealth University Richmond, Virginia
Pages 381-384 | Published online: 11 Jun 2009

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sakkaraiappan Ramalingam & Chandra P Belani. (2002) Taxanes for advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 3:12, pages 1693-1709.
Read now

Articles from other publishers (6)

Anne S. Tsao. 2008. Lung Cancer. Lung Cancer 315 333 .
Jon D. Herrington, Hai T. Tran & Mark W. Riggs. (2005) Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia. Cancer Chemotherapy and Pharmacology 57:2, pages 241-247.
Crossref
Ze Lu, Trini S.-S. Wientjes & Jessie L.-S. Au. (2005) Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors. Pharmaceutical Research 22:7, pages 1069-1078.
Crossref
Vassilis A Georgoulias. (2002) Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 38, pages 61-66.
Crossref
Xavier Bonfill Cosp, Consol Serra, Montse Sacristan, Miquel Nogué, Ferran Losa & Jesús Montesinos. (2002) Second-line chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews.
Crossref
Domenico Ferrigno & Gianfranco Buccheri. (2000) Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?. Lung Cancer 29:2, pages 91-104.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.